Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria E Arango

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
The Biochemical Journal|August 21, 2002
Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysisMasanobu Komatsu, Maria E Arango, Kermit L Carraway
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor modelsCathy Zhang, Zhengming Yan, Maria E Arango, et al.
Current Eye Research|November 16, 2002
An ErbB2-Muc4 complex in rat ocular surface epitheliaJeremy S Swan, Maria E Arango, Coralie A Carothers Carraway, et al.
Oncogene|October 19, 2002
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathwaysScott Jepson, Masanobu Komatsu, Bushra Haq, et al.
Molecular Cancer Therapeutics|December 20, 2007
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaJames G Christensen, Helen Y Zou, Maria E Arango, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 19, 2011
Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor modelsCarleen Cullinane, Donna S Dorow, Susan Jackson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenograftsCathy Zhang, Zhengming Yan, Cory L Painter, et al.
Molecular Cancer Therapeutics|April 17, 2008
Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacyCathy Zhang, Karen Lundgren, Zhengming Yan, et al.
Molecular Cancer Therapeutics|March 6, 2012
Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitorHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Cancer Research|May 8, 2007
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Biochemical Journal|August 21, 2002
Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysisMasanobu Komatsu, Maria E Arango, Kermit L Carraway
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor modelsCathy Zhang, Zhengming Yan, Maria E Arango, et al.
Current Eye Research|November 16, 2002
An ErbB2-Muc4 complex in rat ocular surface epitheliaJeremy S Swan, Maria E Arango, Coralie A Carothers Carraway, et al.
Oncogene|October 19, 2002
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathwaysScott Jepson, Masanobu Komatsu, Bushra Haq, et al.
Molecular Cancer Therapeutics|December 20, 2007
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaJames G Christensen, Helen Y Zou, Maria E Arango, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 19, 2011
Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor modelsCarleen Cullinane, Donna S Dorow, Susan Jackson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenograftsCathy Zhang, Zhengming Yan, Cory L Painter, et al.
Molecular Cancer Therapeutics|April 17, 2008
Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacyCathy Zhang, Karen Lundgren, Zhengming Yan, et al.
Molecular Cancer Therapeutics|March 6, 2012
Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitorHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Cancer Research|May 8, 2007
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Pageof 2